{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:37:05Z","timestamp":1781627825763,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.medcli.2019.09.021","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T22:59:58Z","timestamp":1576364398000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factores asociados a la persistencia a largo plazo de rituximab en artritis reumatoide en la pr\u00e1ctica cl\u00ednica: Estudio RITAR"],"prefix":"10.1016","volume":"155","author":[{"given":"Iciar","family":"Ca\u00f1amares Orbis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Merino Mel\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Llorente Cubas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Bened\u00ed Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garc\u00eda-Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Morell Baladr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidoro","family":"Gonz\u00e1lez-\u00c1lvaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Ram\u00edrez Herraiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10055","key":"10.1016\/j.medcli.2019.09.021_bib0145","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet."},{"issue":"10041","key":"10.1016\/j.medcli.2019.09.021_bib0150","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(16)00380-9","article-title":"Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial","volume":"388","author":"Porter","year":"2016","journal-title":"The Lancet."},{"key":"10.1016\/j.medcli.2019.09.021_bib0155","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s10067-017-3848-6","article-title":"Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies","volume":"36","author":"Einarsson","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.medcli.2019.09.021_bib0160","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/rheumatology\/kex446","article-title":"Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection","volume":"57","author":"Henry","year":"2018","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.medcli.2019.09.021_bib0165","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s10067-015-2977-z","article-title":"Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis","volume":"34","author":"Bredemeier","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.medcli.2019.09.021_bib0170","first-page":"1508","article-title":"Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial","volume":"73","author":"Mariette","year":"2014","journal-title":"ARD"},{"key":"10.1016\/j.medcli.2019.09.021_bib0175","first-page":"39","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial","volume":"70","author":"Tak","year":"2011","journal-title":"ARD"},{"key":"10.1016\/j.medcli.2019.09.021_bib0180","first-page":"3896","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"ARD"},{"key":"10.1016\/j.medcli.2019.09.021_bib0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40744-014-0006-3","article-title":"Comparison of biologic disease-modifying antirheumatic drug therapy persistence between biologics among rheumatoid arthritis patients switching from another biologic","volume":"2","author":"Johnston","year":"2015","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.medcli.2019.09.021_bib0190","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/03009742.2016.1141979","article-title":"Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice","volume":"45","author":"Leon","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.medcli.2019.09.021_bib0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health."},{"key":"10.1016\/j.medcli.2019.09.021_bib0200","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ."},{"key":"10.1016\/j.medcli.2019.09.021_bib0205","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/RHU.0000000000000845","article-title":"Experience with the use of rituximab for the treatment of rheumatoid arthritis in a tertiary hospital in Spain: RITAR Study","volume":"25","author":"Ca\u00f1amares","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.medcli.2019.09.021_bib0210","first-page":"615","article-title":"Rituximab induces a lasting, non-cumulative remodelling of the B-cell compartment","volume":"37","author":"Lopez","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.medcli.2019.09.021_bib0215","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/acr.22327","article-title":"Sustainability of rituximab therapy in different treatment strategies: Results of a 3-year followup of a german biologics register","volume":"66","author":"Richter","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.medcli.2019.09.021_bib0220","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/rheumatology\/key036","article-title":"Long-term persistence with rituximab in patients with rheumatoid arthritis","volume":"57","author":"Oldroyd","year":"2018","journal-title":"Rheumatology."},{"key":"10.1016\/j.medcli.2019.09.021_bib0225","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/CEOR.S124381","article-title":"Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data","volume":"9","author":"Brodszky","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.medcli.2019.09.021_bib0230","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-015-0776-1","article-title":"Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry","volume":"17","author":"Harrold","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.medcli.2019.09.021_bib0235","first-page":"329","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"ARD"},{"key":"10.1016\/j.medcli.2019.09.021_bib0240","unstructured":"Mabthera (rituximab) Ficha t\u00e9cnica rituximab: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios [consultado 30 Abr 2019]. Disponible en: https:\/\/cima.aemps.es\/cima\/pdfs\/ft\/98067002\/FT_98067002.pdf."},{"key":"10.1016\/j.medcli.2019.09.021_bib0245","first-page":"960","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"ARD"},{"key":"10.1016\/j.medcli.2019.09.021_bib0250","unstructured":"Sociedad Espa\u00f1ola de Reumatolog\u00eda. Proyecto EMAR II. Variabilidad en el manejo de la artritis reumatoide y las espondiloartritis en Espa\u00f1a. Informe de Resultados.2011, actualizado 2015 [consultado 15 May 2019]. Disponible en: https:\/\/www.ser.es\/wp-content\/uploads\/2015\/09\/EMAR_Informe.pdf."},{"key":"10.1016\/j.medcli.2019.09.021_bib0255","first-page":"991","article-title":"Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs","volume":"29","author":"Narv\u00e1ez","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.medcli.2019.09.021_bib0260","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.09.021_bib0265","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.semarthrit.2011.06.005","article-title":"Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis","volume":"41","author":"Narv\u00e1ez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.medcli.2019.09.021_bib0270","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/RHU.0000000000000166","article-title":"Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs","volume":"21","author":"Valleala","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.medcli.2019.09.021_bib0275","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/rheumatology\/keu461","article-title":"Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis","volume":"54","author":"Gonz\u00e1lez-\u00c1lvaro","year":"2015","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.medcli.2019.09.021_bib0280","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319306360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319306360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:50:53Z","timestamp":1758419453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775319306360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0025775319306360"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2019.09.021","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factores asociados a la persistencia a largo plazo de rituximab en artritis reumatoide en la pr\u00e1ctica cl\u00ednica: Estudio RITAR","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2019.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}